Biogen Idec Inc (BIIB) 341.18 $BIIB
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 13 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - 2 hrs 46 mins ago
AGN: 213.71 (+1.74), BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), NVS: 95.77 (+0.11)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 50 mins ago
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.56 (-0.07), BIIB: 341.18 (-6.16), GEVA: 81.77 (+0.43), AMGN: 166.55 (-1.52)
Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 341.18 (-6.16), GSK: 45.89 (-0.82), ARRY: 4.47 (+0.56), NVS: 95.77 (+0.11)
Will New Alzheimer's Drug Boost Biogen?
at Investor's Business Daily - Thu Dec 04, 11:32AM CST
Today we'll check in on Biogen Idec (BIIB), which develops treatments for multiple sclerosis, cancer and autoimmune diseases. It's also been working on a drug to slow Alzheimer's, called BIIB-037. Earlier this week, Biogen said it's moving that drug...
BIIB: 341.18 (-6.16)
Stock Market Today: Stocks Worsen Near Midday; Airlines Rally
at Investor's Business Daily - Thu Dec 04, 10:52AM CST
Stocks took a turn for the worse near Thursday's midday, as the Nasdaq erased gains. The S&P 500 and the Dow Jones industrial average lost 0.5% each. Both wiped out all of Wednesday's gains and then some. The Nasdaq fell 0.3% after giving up a 0.2%...
BIIB: 341.18 (-6.16), RYAAY: 68.08 (+4.55), ALK: 56.74 (-0.02), BITA: 78.21 (-1.20), UAL: 61.75 (+2.46)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 341.18 (-6.16), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)
Can the Rally in Biogen (BIIB) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:06AM CST
Can the Rally in Biogen (BIIB) Shares Continue?
BIIB: 341.18 (-6.16)
ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 341.18 (-6.16), ADMA: 10.80 (+0.19), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 341.18 (-6.16), ANIP: 53.45 (-6.76), PRTA: 21.44 (-0.55), AFFX: 9.14 (-0.04)
Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 7:32AM CST
ISIS data by YCharts What: Shares of Isis Pharmaceuticals , a biopharmaceutical company focused on using its proprietary antisense technology platform to develop therapies across a wide range of disease implications, motored ahead by 12% in...
BIIB: 341.18 (-6.16), ISIS: 52.68 (-0.93), AZN: 73.94 (+0.12)
Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 6:21AM CST
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise by nearly 24% on the day.
BIIB: 341.18 (-6.16), SQNM: 3.67 (-0.10), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 341.18 (-6.16), HON: 99.26 (-0.71), UTX: 111.21 (+0.22), KMB: 114.60 (-0.10), INTC: 37.46 (+0.03), PVH: 122.68 (-1.72), SLB: 87.43 (+0.67), PEP: 97.75 (-0.57), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), REGN: 423.21 (-1.20), CSCO: 27.77 (-0.18), MU: 36.07 (-0.03), SWKS: 69.75 (+3.08), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), BA: 131.32 (-0.65), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), ZTS: 44.00 (-0.88), GILD: 101.82 (+0.94), TXN: 55.41 (-0.21), JCP: 6.73 (-0.46), PG: 90.58 (+0.58), PAY: 35.96 (+0.15), SWHC: 9.41 (-0.10)
Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 341.18 (-6.16), PFE: 31.67 (-0.08), PBYI: 195.55 (-2.12)
Stock Market Today: Indexes Close Near Day's Highs
at Investor's Business Daily - Wed Dec 03, 3:25PM CST
The stock market rose Wednesday, closing near session highs for a second straight day. The Nasdaq and S&P 500 climbed 0.4% and the Dow Jones industrial average 0.2%. The Russell 2000 outperformed, rising 1.1%. Volume fell across the board, according...
BIIB: 341.18 (-6.16), GIL: 52.95 (-5.32), GIII: 96.10 (-0.68), ADI: 56.62 (+0.11)
Biogen: Big Biotech Play Ready To Move
Bret Jensen - at Seeking Alpha - Wed Dec 03, 2:30PM CST
BIIB: 341.18 (-6.16)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 341.18 (-6.16), UTHR: 129.05 (-3.30)
Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:33PM CST
Biogen (BIIB) reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037, for the treatment of Alzheimer.
BIIB: 341.18 (-6.16), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)
Myriad Genetics' Prolaris: A Pocket-Friendly Cancer Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:00PM CST
Myriad Genetics' (MYGN) Prolaris is the first prognostic test that allows a healthcare provider to directly measure the molecular biology of an individual patient's prostate cancer.
BIIB: 341.18 (-6.16), MYGN: 34.68 (+0.13), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Jim Cramer on the Stock Market: You Have to Love Biotech
at The Street - Wed Dec 03, 11:29AM CST
In this era of turmoil, investors can take comfort in this sector.
BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03), REGN: 423.21 (-1.20), NVS: 95.77 (+0.11), CELG: 113.63 (-0.60)
Hot Drugmakers Build More Labs, Grab Space In Boston
at Investor's Business Daily - 1 hr 13 mins ago
The greater Boston area has seen an influx of some fast-growing biotechs like Biogen Idec (BIIB) that have been taking lab space, a trend that's driven down vacancy rates in a big way. That's under way while the the biotech sector is surging -- IBD's...
BIIB: 341.18 (-6.16), ARE: 88.12 (+1.73), GILD: 101.82 (+0.94), BAX: 73.57 (-0.16), PFE: 31.67 (-0.08), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03)
Gilead Sciences: An Alpha Stock Through The Good And Bad Times
Michael Grogan - at Seeking Alpha - 2 hrs 46 mins ago
AGN: 213.71 (+1.74), BIIB: 341.18 (-6.16), GILD: 101.82 (+0.94), AMGN: 166.55 (-1.52), NVS: 95.77 (+0.11)
Synageva Completes BLA Submission for Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 50 mins ago
Synageva BioPharma Corp. (GEVA) announced the completion of the rolling submission of a biologics license application to the FDA for sebelipase alfa for LAL deficiency.
CYTK: 4.56 (-0.07), BIIB: 341.18 (-6.16), GEVA: 81.77 (+0.43), AMGN: 166.55 (-1.52)
Array BioPharma Regains Binimetinib Rights from Novartis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 2:00PM CST
Shares of Array BioPharma Inc. (ARRY) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis (NVS) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.
BIIB: 341.18 (-6.16), GSK: 45.89 (-0.82), ARRY: 4.47 (+0.56), NVS: 95.77 (+0.11)
Will New Alzheimer's Drug Boost Biogen?
at Investor's Business Daily - Thu Dec 04, 11:32AM CST
Today we'll check in on Biogen Idec (BIIB), which develops treatments for multiple sclerosis, cancer and autoimmune diseases. It's also been working on a drug to slow Alzheimer's, called BIIB-037. Earlier this week, Biogen said it's moving that drug...
BIIB: 341.18 (-6.16)
Stock Market Today: Stocks Worsen Near Midday; Airlines Rally
at Investor's Business Daily - Thu Dec 04, 10:52AM CST
Stocks took a turn for the worse near Thursday's midday, as the Nasdaq erased gains. The S&P 500 and the Dow Jones industrial average lost 0.5% each. Both wiped out all of Wednesday's gains and then some. The Nasdaq fell 0.3% after giving up a 0.2%...
BIIB: 341.18 (-6.16), RYAAY: 68.08 (+4.55), ALK: 56.74 (-0.02), BITA: 78.21 (-1.20), UAL: 61.75 (+2.46)
The Zacks Analyst Blog Highlights: Biogen Idec, Eli Lilly, AstraZeneca and Amgen
PR Newswire - Thu Dec 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Biogen Idec Inc. (Nasdaq:BIIB-Free Report), Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report) and Amgen Inc. (Nasdaq:AMGN-Free Report).
BIIB: 341.18 (-6.16), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)
Can the Rally in Biogen (BIIB) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:06AM CST
Can the Rally in Biogen (BIIB) Shares Continue?
BIIB: 341.18 (-6.16)
ADMA Biologics Slumps: ADMA Tanks 11% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:53AM CST
ADMA Biologics has been witnessing a positive trend in its current year estimate revision and its share price has been falling for past few days
BIIB: 341.18 (-6.16), ADMA: 10.80 (+0.19), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 341.18 (-6.16), ANIP: 53.45 (-6.76), PRTA: 21.44 (-0.55), AFFX: 9.14 (-0.04)
Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 7:32AM CST
ISIS data by YCharts What: Shares of Isis Pharmaceuticals , a biopharmaceutical company focused on using its proprietary antisense technology platform to develop therapies across a wide range of disease implications, motored ahead by 12% in...
BIIB: 341.18 (-6.16), ISIS: 52.68 (-0.93), AZN: 73.94 (+0.12)
Sequenom Inc. (SQNM) in Focus: Stock Surges 23.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 6:21AM CST
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rise by nearly 24% on the day.
BIIB: 341.18 (-6.16), SQNM: 3.67 (-0.10), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Cramer's Mad Money - PVH Fits Well At A Discount (12/3/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 04, 5:04AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 3. CEO interview: Manny Chirico, PVH (NYSE: PVH ). Other stock mentioned: J.C. Penney (NYSE: JCP ) PVH ( PVH ) delivered an 8 cent earnings...
BIIB: 341.18 (-6.16), HON: 99.26 (-0.71), UTX: 111.21 (+0.22), KMB: 114.60 (-0.10), INTC: 37.46 (+0.03), PVH: 122.68 (-1.72), SLB: 87.43 (+0.67), PEP: 97.75 (-0.57), GWPH: 74.55 (-1.46), EOG: 93.00 (+1.20), REGN: 423.21 (-1.20), CSCO: 27.77 (-0.18), MU: 36.07 (-0.03), SWKS: 69.75 (+3.08), HAL: 40.74 (-0.01), SN: 9.06 (-0.88), BMY: 58.89 (-0.14), BA: 131.32 (-0.65), HPQ: 39.07 (+0.02), CELG: 113.63 (-0.60), ZTS: 44.00 (-0.88), GILD: 101.82 (+0.94), TXN: 55.41 (-0.21), JCP: 6.73 (-0.46), PG: 90.58 (+0.58), PAY: 35.96 (+0.15), SWHC: 9.41 (-0.10)
Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 4:10PM CST
Shares of Puma Biotechnology, Inc. (PBYI) plunged significantly in after-market hours trading following the company's announcement that the NDA on pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016.
BIIB: 341.18 (-6.16), PFE: 31.67 (-0.08), PBYI: 195.55 (-2.12)
Stock Market Today: Indexes Close Near Day's Highs
at Investor's Business Daily - Wed Dec 03, 3:25PM CST
The stock market rose Wednesday, closing near session highs for a second straight day. The Nasdaq and S&P 500 climbed 0.4% and the Dow Jones industrial average 0.2%. The Russell 2000 outperformed, rising 1.1%. Volume fell across the board, according...
BIIB: 341.18 (-6.16), GIL: 52.95 (-5.32), GIII: 96.10 (-0.68), ADI: 56.62 (+0.11)
Biogen: Big Biotech Play Ready To Move
Bret Jensen - at Seeking Alpha - Wed Dec 03, 2:30PM CST
BIIB: 341.18 (-6.16)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 341.18 (-6.16), UTHR: 129.05 (-3.30)
Biogen Up on Encouraging Interim Data on Alzheimer's Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:33PM CST
Biogen (BIIB) reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037, for the treatment of Alzheimer.
BIIB: 341.18 (-6.16), AZN: 73.94 (+0.12), AMGN: 166.55 (-1.52), LLY: 72.38 (+1.25)
Myriad Genetics' Prolaris: A Pocket-Friendly Cancer Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 1:00PM CST
Myriad Genetics' (MYGN) Prolaris is the first prognostic test that allows a healthcare provider to directly measure the molecular biology of an individual patient's prostate cancer.
BIIB: 341.18 (-6.16), MYGN: 34.68 (+0.13), ANIP: 53.45 (-6.76), AFFX: 9.14 (-0.04)
Jim Cramer on the Stock Market: You Have to Love Biotech
at The Street - Wed Dec 03, 11:29AM CST
In this era of turmoil, investors can take comfort in this sector.
BIIB: 341.18 (-6.16), AVNR: 16.96 (+0.04), AMGN: 166.55 (-1.52), AGIO: 104.05 (+2.03), REGN: 423.21 (-1.20), NVS: 95.77 (+0.11), CELG: 113.63 (-0.60)
